Prof Benjamin Besse speaks to ecancer about the results from the phase 3 CARMEN-LC03 trial.

The study compared tusamitamab ravtansine to docetaxel in patients with advanced non-squamous NSCLC who had previously received platinum-based chemotherapy and immunotherapy, and whose tumours highly expressed CEACAM5.

The study presented results from the final progression-free survival and the first interim overall survival analyses.

The results showed that although there were trends favouring tusamitamab ravtansine in interim overall survival and electronic patient-reported outcomes analysis, the study did not meet its dual primary endpoint of improving the progression-free survival as per central review.

However, tusamitamab ravtansine showed better safety in various important clinical categories.